EGFR and small cell lung carcinoma: In a similar case of composite lung cancer, with both the adenocarcinoma and SCLC components harboring EGFR exon 19 deletion, TP53, and RB1 loss, osimertinib obtained a PFS of eight months and, continued beyond progression, pleural effusion control for over 12 months [44].